No Data
10-K/A: Annual report (Amendment)
This ATyr Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Piper Sandler Maintains EnGene Holdings(ENGN.US) With Buy Rating, Maintains Target Price $26
Piper Sandler Initiates EnGene Holdings(ENGN.US) With Buy Rating, Announces Target Price $26
Buy Rating for EnGene Holdings: Strategic Positioning and Growth Potential in NMIBC Market
Express News | EnGene Holdings Inc : Piper Sandler Initiates Coverage With Overweight Rating; Price Target $26
Wins333 : Thanks for the update, but market responses otherwise got be something hidden
Jaguar8 OP Wins333 : Nowadays, I notice that market reaction tends to be delayed
Wins333 Jaguar8 OP : Agreed bro, I think that’s deliberated. I will say you have a great sense